Frontier Asset Management LLC Cuts Position in Abbott Laboratories $ABT

Frontier Asset Management LLC lessened its stake in Abbott Laboratories (NYSE:ABT) by 34.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,682 shares of the healthcare product maker’s stock after selling 11,055 shares during the quarter. Frontier Asset Management LLC’s holdings in Abbott Laboratories were worth $2,591,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Centerpoint Advisory Group raised its holdings in shares of Abbott Laboratories by 84.0% in the 4th quarter. Centerpoint Advisory Group now owns 2,848 shares of the healthcare product maker’s stock worth $357,000 after purchasing an additional 1,300 shares during the period. NewEdge Wealth LLC raised its holdings in shares of Abbott Laboratories by 20.0% in the 4th quarter. NewEdge Wealth LLC now owns 59,747 shares of the healthcare product maker’s stock worth $7,486,000 after purchasing an additional 9,944 shares during the period. Triton Financial Group Inc raised its holdings in shares of Abbott Laboratories by 3.1% in the 4th quarter. Triton Financial Group Inc now owns 18,053 shares of the healthcare product maker’s stock worth $2,262,000 after purchasing an additional 540 shares during the period. Drucker Wealth 3.0 LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $1,420,000. Finally, RB Capital Management LLC raised its holdings in shares of Abbott Laboratories by 25.4% in the 4th quarter. RB Capital Management LLC now owns 51,282 shares of the healthcare product maker’s stock worth $6,425,000 after purchasing an additional 10,373 shares during the period. Institutional investors own 75.18% of the company’s stock.

Insider Activity

In other news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 3,055 shares of company stock worth $353,097. Company insiders own 0.46% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Medical Devices segment delivered 8.5% Q1 growth, with electrophysiology, rhythm management, and heart failure products driving gains. That reinforces the company’s long-term growth story and suggests its device portfolio remains a key catalyst for ABT. Abbott’s Medical Device Strategy Supports Long-Term Growth Outlook
• Positive Sentiment: Wall Street analysts remain bullish on Abbott Laboratories despite its recent underperformance versus the broader market, which can help cushion sentiment around the stock. Abbott Laboratories Stock: Analyst Estimates & Ratings
• Positive Sentiment: Wells Fargo reaffirmed its Buy rating on ABT, adding to the view that analysts still see upside potential despite near-term weakness. Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
• Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for Abbott to $5.47 from $5.48, which is only a minor change and close to consensus, so the impact looks limited. Abbott Laboratories news item referencing Erste Group Bank estimate reduction
• Negative Sentiment: ABT has underperformed over the past year, and recent share-price weakness has kept investors focused on whether the stock is now cheap rather than on a strong near-term rebound. Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness?

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Leerink Partners lowered their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. Stifel Nicolaus lowered their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. BTIG Research reissued a “buy” rating and set a $131.00 target price on shares of Abbott Laboratories in a report on Monday, April 27th. Citigroup lowered their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $119.43.

Abbott Laboratories Stock Down 3.2%

ABT opened at $84.24 on Friday. The company has a fifty day moving average price of $102.69 and a 200-day moving average price of $115.09. The firm has a market capitalization of $146.72 billion, a P/E ratio of 23.60, a price-to-earnings-growth ratio of 1.41 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a one year low of $84.08 and a one year high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.